Know Cancer

or
forgot password

the Role of COX-2 Inhibitor(CELECOXIB) in Combination With Chemoradiation in Locally Advanced Head & Neck Carcinoma, Phase III Randomized Clinical Trial


Phase 3
20 Years
N/A
Open (Enrolling)
Both
Head and Neck Cancer

Thank you

Trial Information

the Role of COX-2 Inhibitor(CELECOXIB) in Combination With Chemoradiation in Locally Advanced Head & Neck Carcinoma, Phase III Randomized Clinical Trial


Inclusion Criteria:



- stage III/IV (locally advanced) carcinoma of oropharynx, oral cavity, hypopharynx,
larynx, or nasopharynx

- primary treatment with chemoradiation

Exclusion Criteria:

- distant metastasis

- incomplete treatment

- adjuvant chemoradiation after surgery without apparent tumor

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment

Outcome Measure:

efficacy of celecoxib (response rate and local control)

Outcome Time Frame:

30 months

Safety Issue:

Yes

Principal Investigator

Mahdi Aghili, MD

Investigator Role:

Study Chair

Investigator Affiliation:

cancer institute center

Authority:

Iran: Ministry of Health

Study ID:

3058

NCT ID:

NCT00603759

Start Date:

April 2006

Completion Date:

August 2009

Related Keywords:

  • Head and Neck Cancer
  • COX2 inhibitor
  • head and neck cancer
  • chemoradiation
  • Carcinoma
  • Head and Neck Neoplasms

Name

Location